Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company is bringing precision therapies for gynaecological cancers
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
This project shall be implemented through incorporation of a new joint venture company in Zambia
Subscribe To Our Newsletter & Stay Updated